Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Breast Neoplasms 10Colorectal Neoplasms 8Lung Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Pancreatic Neoplasms 5Neoplastic Cells, Circulating 4Neoplasm Metastasis 4Biliary Tract Neoplasms 4Recurrence 3Prostatic Neoplasms 3Oropharyngeal Neoplasms 3Neoplasm, Residual 3Disease 3Squamous Cell Carcinoma of Head and Neck 2Nevi and Melanomas 2Neuroendocrine Tumors 2Nasopharyngeal Carcinoma 2NSCLC 2Melanoma 2Head and Neck Neoplasms 2Cholangiocarcinoma 2Carcinoma, Hepatocellular 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Smoking 1Sarcoma, Ewing 1

Interventions

Imatinib Mesylate 32regorafenib 9Sunitinib 9Laparoscopy 5Dasatinib 4Blood Specimen Collection 4pazopanib 3nilotinib 3Surveys and Questionnaires 3Surgical Procedures, Operative 3Paclitaxel 3Observation 3spartalizumab 2ripretinib 2envafolimab 2binimetinib 2apatinib 2Temozolomide 2Neoadjuvant Therapy 2Ipilimumab 2Gemcitabine 2Docetaxel 2Cisplatin 2Carboplatin 2Capecitabine 2CTLA-4 Antigen 2Biopsy, Fine-Needle 2Biopsy 25-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide 24-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Gastrointestinal Stromal Tumors × Liquid Biopsy × Clear all
NCT05408897 2022-09-21

Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRD

Peking University People's Hospital

Recruiting
45 enrolled
GastrointestinalSarcoma

Neoplasm, Residual, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡